Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Cutting Sugary Drink Sales by 20% Through Education, Not a Tax
November 13th 2016The results from a wide-ranging public health effort in Howard County, Maryland, show a decline in sugary beverage consumption nearly on par with early results from Berkeley, California, which passed the nation's first soda tax.
Will Trump Take Steps to Rein in Drug Prices?
November 11th 2016A transition statement on healthcare makes no mention of prescription drug prices, despite Trump's strong positions as a candidate. A pharmaceutical executive, former Christie Administration Chief of Staff Rich Bagger, took leave in July to run the Trump transition.
5 Things From the Task Force on Mental Health Parity
November 4th 2016Audits, consumer education, and help for states were among the recommendations to force better compliance with the 2008 law, which seeks to ensure that coverage for mental health or substance abuse disorders mirrors other benefits in a health plan.
CMS Sets Eligibility Rules for Medicare Diabetes Prevention Program
November 3rd 2016The program has been shown to reduce by 58% the likelihood of progressing to type 2 diabetes. Reimbursement details are still being worked out, but CMS clarified that Medicare patients will not be subject to cost-sharing.
Public Wants Next President, Congress to Tackle Drug Prices
October 28th 2016Frustration with high prescription drug prices remains an issue that cuts across party lines. Majorities of Democrats, Republicans, and independents want the government to protect access to high-cost treatments for those with chronic conditions.